Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
出版年份 2021 全文链接
标题
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
作者
关键词
Melanoma, Targeted therapy, Immunotherapy, Pembrolizumab, Encorafenib, Binimetinib, Phase I
出版物
EUROPEAN JOURNAL OF CANCER
Volume 158, Issue -, Pages 72-84
出版商
Elsevier BV
发表日期
2021-10-15
DOI
10.1016/j.ejca.2021.09.011
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
- (2020) Mallika Lala et al. EUROPEAN JOURNAL OF CANCER
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
- (2020) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Triple therapy for BRAFV600-mutated melanoma
- (2020) Antoni Ribas LANCET
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
- (2020) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
- (2020) Reinhard Dummer et al. NATURE MEDICINE
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
- (2020) Reinhard Dummer et al. JAMA Oncology
- EASL Clinical Practice Guidelines: Drug-induced liver injury
- (2019) Raúl Andrade et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Melanoma
- (2018) Dirk Schadendorf et al. LANCET
- Design considerations for early-phase clinical trials of immune-oncology agents
- (2018) Nolan A. Wages et al. Journal for ImmunoTherapy of Cancer
- Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
- (2018) Pavel Mozgunov et al. Journal of Biopharmaceutical Statistics
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
- (2015) S. Postel-Vinay et al. ANNALS OF ONCOLOGY
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature
- (2014) M.- K. Riviere et al. ANNALS OF ONCOLOGY
- Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN
- (2014) P.-C. Ho et al. CANCER RESEARCH
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature
- (2011) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More